Navigation Links
NuVasive to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:9/8/2009

SAN DIEGO, Sept. 8 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer, and Kevin O'Boyle, Executive Vice President and Chief Financial Officer, are scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference at The Grand Hyatt in New York, New York, on Monday, September 14, 2009, at 11:30 a.m. ET.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With nearly 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:                           Investors:
    Kevin C. O'Boyle                   Patrick F. Williams
    EVP & Chief Financial Officer      Vice President, Finance &
    NuVasive, Inc.                      Investor Relations
    858-909-1998                       NuVasive, Inc.
    investorrelations@nuvasive.com     858-638-5511
                                       investorrelations@nuvasive.com

                                       Media:
                                       Jason Rando
                                       The Ruth Group
                                       646-536-7025
                                       jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at the Thomas Weisel Annual Healthcare Conference
2. NuVasive Announces Upcoming Departure of Chief Financial Officer
3. NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
4. NuVasive Reports Second Quarter 2009 Financial Results
5. NuVasive to Present at the 8th Annual Needham Life Sciences Conference
6. NuVasive to Present at the 2009 William Blair Growth Stock Conference
7. NuVasive to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference
8. NuVasive Reports First Quarter 2009 Financial Results
9. NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
10. NuVasive Announces Conference Call and Webcast of First Quarter 2009 Results
11. NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, marks World ... on public health. The World Veterinary Association (WVA) and the World Organization for ... continuing education with a One Health focus, which emphasizes how veterinarians pursue continuing ...
(Date:4/30/2016)... ... ... for all of us, but there are things we can do to improve the odds of ... more and more that there are simple, yet important steps that can be taken to maintain ... Kohli’s recommends for her patients include;, , exercise , ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... Mercy College ... campus. The following programs will be expanding due to high demand: Master of ... The expansion will begin this summer. , School of Business Graduate Program ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation for ... first accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology: